1.The influence of Jiuganning decoction on the content of CYP2E1 and cytokine IL-6,TNF in rats models of alcoholic hepatic injury
International Journal of Traditional Chinese Medicine 2011;33(4):305-308
Objective To explore the influences of Jinganning decoction on the content of CYP2E1 and cytokine IL-6,TNF in rats models of alcohdic hepatic injury.Methos 72 male Wistar clean level rats were randomly divided into 6 groups:blank control group,Jiuganning drug toxicity test group,alcoholic hepatic disease model group,Yiganling treatment group,Jiuganning low dose group,and Jiuganning high dose group.Blank control group was treated with physiological saline;Jiuganning drug toxicity test group was treated with Jiuganning decoction to observe toxicity and side effects.Jiuganning low and high dose treatment group were treated with 17.5 g/kg and 23.5 g/kg crude drug.Yiganning treatment group were treated with 0.206 g/kg crude drug.After 4 weeks'treatment,the content of TNF,IL-6,MDA as well as the activity of CYP2E1 and SOD were measured.Results Compared with the alcoholic hepatic disease model group,the content of IL-6(F=46.281,9.101),TNF and the activity (F=62.537)of CYP2E1 of all treatment group were significantly improved(P<0.01).The content of SOD(F=19.210)in the rats serum of all treatment group was significantly increased while the MDA(F=34.952)was decreased.All the indexes in the treatment group had significant differences with the alcoholic hepatic disease and model group(P<0.01).Conclusions The mechanism of Jiuganning decoction can effectively reduce the content of CYP2E1 and IL-6,TNF-a,with the changes of cell physiopathology and the influences of relevant enzymes,reveals the functional routines of the decoction treating hepatic injury:anti-lipid peroxidative,adjusting cytokine's activity,protecting hepatocyte,palliating the hepatocyte inflammation,and easing fibration.
2.A methodological study of traditional Chinese medicine treatment of primary liver cancer
Weiqin WANG ; Zhanhua GAO ; Changjian YIN
Journal of Clinical Hepatology 2021;37(9):2009-2015.
With in-depth studies on the etiology and pathogenesis, pathological viscera and bowels, and rule of disease progression of primary liver cancer in recent years, some clinical and experimental results have been achieved for the treatment of primary liver cancer with traditional Chinese medicine, such as treatment based on syndrome differentiation and disease differentiation, compound prescriptions and monomers of Chinese herbs, oral administration of drugs/acupuncture and moxibustion/external application, and prevention before disease onset and prevention of recurrence, which reflects the rich methodological connotations of traditional Chinese medicine and lays a foundation for constructing a new diagnostic and therapeutic mode for liver cancer based on integrated traditional Chinese and Western medicine therapy.
3.Chinese expert consensus on emergency surgery for severe trauma and infection prevention during corona virus disease 2019 epidemic (version 2023)
Yang LI ; Yuchang WANG ; Haiwen PENG ; Xijie DONG ; Guodong LIU ; Wei WANG ; Hong YAN ; Fan YANG ; Ding LIU ; Huidan JING ; Yu XIE ; Manli TANG ; Xian CHEN ; Wei GAO ; Qingshan GUO ; Zhaohui TANG ; Hao TANG ; Bingling HE ; Qingxiang MAO ; Zhen WANG ; Xiangjun BAI ; Daqing CHEN ; Haiming CHEN ; Min DAO ; Dingyuan DU ; Haoyu FENG ; Ke FENG ; Xiang GAO ; Wubing HE ; Peiyang HU ; Xi HU ; Gang HUANG ; Guangbin HUANG ; Wei JIANG ; Hongxu JIN ; Laifa KONG ; He LI ; Lianxin LI ; Xiangmin LI ; Xinzhi LI ; Yifei LI ; Zilong LI ; Huimin LIU ; Changjian LIU ; Xiaogang MA ; Chunqiu PAN ; Xiaohua PAN ; Lei PENG ; Jifu QU ; Qiangui REN ; Xiguang SANG ; Biao SHAO ; Yin SHEN ; Mingwei SUN ; Fang WANG ; Juan WANG ; Jun WANG ; Wenlou WANG ; Zhihua WANG ; Xu WU ; Renju XIAO ; Yang XIE ; Feng XU ; Xinwen YANG ; Yuetao YANG ; Yongkun YAO ; Changlin YIN ; Yigang YU ; Ke ZHANG ; Xingwen ZHANG ; Guixi ZHANG ; Gang ZHAO ; Xiaogang ZHAO ; Xiaosong ZHU ; Yan′an ZHU ; Changju ZHU ; Zhanfei LI ; Lianyang ZHANG
Chinese Journal of Trauma 2023;39(2):97-106
During coronavirus disease 2019 epidemic, the treatment of severe trauma has been impacted. The Consensus on emergency surgery and infection prevention and control for severe trauma patients with 2019 novel corona virus pneumonia was published online on February 12, 2020, providing a strong guidance for the emergency treatment of severe trauma and the self-protection of medical staffs in the early stage of the epidemic. With the Joint Prevention and Control Mechanism of the State Council renaming "novel coronavirus pneumonia" to "novel coronavirus infection" and the infection being managed with measures against class B infectious diseases since January 8, 2023, the consensus published in 2020 is no longer applicable to the emergency treatment of severe trauma in the new stage of epidemic prevention and control. In this context, led by the Chinese Traumatology Association, Chinese Trauma Surgeon Association, Trauma Medicine Branch of Chinese International Exchange and Promotive Association for Medical and Health Care, and Editorial Board of Chinese Journal of Traumatology, the Chinese expert consensus on emergency surgery for severe trauma and infection prevention during coronavirus disease 2019 epidemic ( version 2023) is formulated to ensure the effectiveness and safety in the treatment of severe trauma in the new stage. Based on the policy of the Joint Prevention and Control Mechanism of the State Council and by using evidence-based medical evidence as well as Delphi expert consultation and voting, 16 recommendations are put forward from the four aspects of the related definitions, infection prevention, preoperative assessment and preparation, emergency operation and postoperative management, hoping to provide a reference for severe trauma care in the new stage of the epidemic prevention and control.